ADMA markets & develops plasma derived products to treat Primary Immune Deficiency Disease (PIDD) and certain other infectious diseases
10/25/18 PDUFA
After a previous CRL due to mfrng issues at a third party facility, ADMA acquired the mfr and its products then addressed the issues internally
Plasma derived proteins are not subject to patents, instead quant methods to reliably test for appropriate levels of neutralizing antibodies are patentable
CEO & CFO bought a combined 57,000 shares at $4.78
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.